Literature DB >> 28385496

ANGPTL3 Deficiency and Protection Against Coronary Artery Disease.

Nathan O Stitziel1, Amit V Khera2, Xiao Wang3, Andrew J Bierhals4, A Christina Vourakis5, Alexandra E Sperry5, Pradeep Natarajan2, Derek Klarin6, Connor A Emdin2, Seyedeh M Zekavat7, Akihiro Nomura2, Jeanette Erdmann8, Heribert Schunkert9, Nilesh J Samani10, William E Kraus11, Svati H Shah11, Bing Yu12, Eric Boerwinkle12, Daniel J Rader13, Namrata Gupta7, Philippe M Frossard14, Asif Rasheed14, John Danesh15, Eric S Lander7, Stacey Gabriel7, Danish Saleheen16, Kiran Musunuru17, Sekar Kathiresan18.   

Abstract

BACKGROUND: Familial combined hypolipidemia, a Mendelian condition characterized by substantial reductions in all 3 major lipid fractions, is caused by mutations that inactivate the gene angiopoietin-like 3 (ANGPTL3). Whether ANGPTL3 deficiency reduces risk of coronary artery disease (CAD) is unknown.
OBJECTIVES: The study goal was to leverage 3 distinct lines of evidence-a family that included individuals with complete (compound heterozygote) ANGPTL3 deficiency, a population based-study of humans with partial (heterozygote) ANGPTL3 deficiency, and biomarker levels in patients with myocardial infarction (MI)-to test whether ANGPTL3 deficiency is associated with lower risk for CAD.
METHODS: We assessed coronary atherosclerotic burden in 3 individuals with complete ANGPTL3 deficiency and 3 wild-type first-degree relatives using computed tomography angiography. In the population, ANGPTL3 loss-of-function (LOF) mutations were ascertained in up to 21,980 people with CAD and 158,200 control subjects. LOF mutations were defined as nonsense, frameshift, and splice-site variants, along with missense variants resulting in <25% of wild-type ANGPTL3 activity in a mouse model. In a biomarker study, circulating ANGPTL3 concentration was measured in 1,493 people who presented with MI and 3,232 control subjects.
RESULTS: The 3 individuals with complete ANGPTL3 deficiency showed no evidence of coronary atherosclerotic plaque. ANGPTL3 gene sequencing demonstrated that approximately 1 in 309 people was a heterozygous carrier for an LOF mutation. Compared with those without mutation, heterozygous carriers of ANGPTL3 LOF mutations demonstrated a 17% reduction in circulating triglycerides and a 12% reduction in low-density lipoprotein cholesterol. Carrier status was associated with a 34% reduction in odds of CAD (odds ratio: 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04). Individuals in the lowest tertile of circulating ANGPTL3 concentrations, compared with the highest, had reduced odds of MI (adjusted odds ratio: 0.65; 95% confidence interval: 0.55 to 0.77; p < 0.001).
CONCLUSIONS: ANGPTL3 deficiency is associated with protection from CAD.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  human genetics; loss-of-function mutations; myocardial infarction

Mesh:

Substances:

Year:  2017        PMID: 28385496      PMCID: PMC5404817          DOI: 10.1016/j.jacc.2017.02.030

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  42 in total

1.  Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase.

Authors:  Mitsuru Shimamura; Morihiro Matsuda; Hiroaki Yasumo; Mitsuyo Okazaki; Kazunori Fujimoto; Keita Kono; Tetsuya Shimizugawa; Yosuke Ando; Ryuta Koishi; Takafumi Kohama; Naohiko Sakai; Kazuaki Kotani; Ryutaro Komuro; Tatsuo Ishida; Kenichi Hirata; Shizuya Yamashita; Hidehiko Furukawa; Iichiro Shimomura
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-16       Impact factor: 8.311

2.  ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.

Authors:  Viktoria Gusarova; Corey A Alexa; Yan Wang; Ashique Rafique; Jee Hae Kim; David Buckler; Ivory J Mintah; Lisa M Shihanian; Jonathan C Cohen; Helen H Hobbs; Yurong Xin; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  J Lipid Res       Date:  2015-05-11       Impact factor: 5.922

3.  No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.

Authors: 
Journal:  Circulation       Date:  2003-03-04       Impact factor: 29.690

4.  Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits.

Authors:  Nidhi Mehta; Arman Qamar; Liming Qu; Atif N Qasim; Nehal N Mehta; Muredach P Reilly; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03-13       Impact factor: 8.311

5.  Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism.

Authors:  Ilenia Minicocci; Anna Tikka; Eleonora Poggiogalle; Jari Metso; Anna Montali; Fabrizio Ceci; Giancarlo Labbadia; Mario Fontana; Alessia Di Costanzo; Marianna Maranghi; Aldo Rosano; Christian Ehnholm; Lorenzo Maria Donini; Matti Jauhiainen; Marcello Arca
Journal:  J Lipid Res       Date:  2016-04-03       Impact factor: 5.922

6.  A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex.

Authors:  Robert W Davies; George A Wells; Alexandre F R Stewart; Jeanette Erdmann; Svati H Shah; Jane F Ferguson; Alistair S Hall; Sonia S Anand; Mary S Burnett; Stephen E Epstein; Sonny Dandona; Li Chen; Janja Nahrstaedt; Christina Loley; Inke R König; William E Kraus; Christopher B Granger; James C Engert; Christian Hengstenberg; H-Erich Wichmann; Stefan Schreiber; W H Wilson Tang; Stephen G Ellis; Daniel J Rader; Stanley L Hazen; Muredach P Reilly; Nilesh J Samani; Heribert Schunkert; Robert Roberts; Ruth McPherson
Journal:  Circ Cardiovasc Genet       Date:  2012-02-07

7.  The Pakistan Risk of Myocardial Infarction Study: a resource for the study of genetic, lifestyle and other determinants of myocardial infarction in South Asia.

Authors:  Danish Saleheen; Moazzam Zaidi; Asif Rasheed; Usman Ahmad; Abdul Hakeem; Muhammed Murtaza; Waleed Kayani; Azhar Faruqui; Assadullah Kundi; Khan Shah Zaman; Zia Yaqoob; Liaquat Ali Cheema; Abdus Samad; Syed Zahed Rasheed; Nadeem Hayat Mallick; Muhammad Azhar; Rashid Jooma; Ali Raza Gardezi; Nazir Memon; Abdul Ghaffar; Nadir Khan; Nabi Shah; Asad Ali Shah; Maria Samuel; Farina Hanif; Madiha Yameen; Sobia Naz; Aisha Sultana; Aisha Nazir; Shehzad Raza; Muhammad Shazad; Sana Nasim; Muhammad Ahsan Javed; Syed Saadat Ali; Mehmood Jafree; Muhammad Imran Nisar; Muhammad Salman Daood; Altaf Hussain; Nadeem Sarwar; Ayeesha Kamal; Panos Deloukas; Muhammad Ishaq; Philippe Frossard; John Danesh
Journal:  Eur J Epidemiol       Date:  2009-04-30       Impact factor: 8.082

8.  Inactivating mutations in NPC1L1 and protection from coronary heart disease.

Authors:  Nathan O Stitziel; Hong-Hee Won; Alanna C Morrison; Gina M Peloso; Ron Do; Leslie A Lange; Pierre Fontanillas; Namrata Gupta; Stefano Duga; Anuj Goel; Martin Farrall; Danish Saleheen; Paola Ferrario; Inke König; Rosanna Asselta; Piera A Merlini; Nicola Marziliano; Maria Francesca Notarangelo; Ursula Schick; Paul Auer; Themistocles L Assimes; Muredach Reilly; Robert Wilensky; Daniel J Rader; G Kees Hovingh; Thomas Meitinger; Thorsten Kessler; Adnan Kastrati; Karl-Ludwig Laugwitz; David Siscovick; Jerome I Rotter; Stanely L Hazen; Russell Tracy; Sharon Cresci; John Spertus; Rebecca Jackson; Stephen M Schwartz; Pradeep Natarajan; Jacy Crosby; Donna Muzny; Christie Ballantyne; Stephen S Rich; Christopher J O'Donnell; Goncalo Abecasis; Shamil Sunaev; Deborah A Nickerson; Julie E Buring; Paul M Ridker; Daniel I Chasman; Erin Austin; Iftikhar J Kullo; Peter E Weeke; Christian M Shaffer; Lisa A Bastarache; Joshua C Denny; Dan M Roden; Colin Palmer; Panos Deloukas; Dan-Yu Lin; Zheng-zheng Tang; Jeanette Erdmann; Heribert Schunkert; John Danesh; Jaume Marrugat; Roberto Elosua; Diego Ardissino; Ruth McPherson; Hugh Watkins; Alex P Reiner; James G Wilson; David Altshuler; Richard A Gibbs; Eric S Lander; Eric Boerwinkle; Stacey Gabriel; Sekar Kathiresan
Journal:  N Engl J Med       Date:  2014-11-12       Impact factor: 91.245

9.  Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease.

Authors:  Anna Helgadottir; Solveig Gretarsdottir; Gudmar Thorleifsson; Eirikur Hjartarson; Asgeir Sigurdsson; Audur Magnusdottir; Aslaug Jonasdottir; Helgi Kristjansson; Patrick Sulem; Asmundur Oddsson; Gardar Sveinbjornsson; Valgerdur Steinthorsdottir; Thorunn Rafnar; Gisli Masson; Ingileif Jonsdottir; Isleifur Olafsson; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Maryam S Daneshpour; Davood Khalili; Fereidoun Azizi; Dorine W Swinkels; Lambertus Kiemeney; Arshed A Quyyumi; Allan I Levey; Riyaz S Patel; Salim S Hayek; Ingibjorg J Gudmundsdottir; Gudmundur Thorgeirsson; Unnur Thorsteinsdottir; Daniel F Gudbjartsson; Hilma Holm; Kari Stefansson
Journal:  Nat Genet       Date:  2016-05-02       Impact factor: 41.307

10.  Distribution and medical impact of loss-of-function variants in the Finnish founder population.

Authors:  Elaine T Lim; Peter Würtz; Aki S Havulinna; Priit Palta; Taru Tukiainen; Karola Rehnström; Tõnu Esko; Reedik Mägi; Michael Inouye; Tuuli Lappalainen; Yingleong Chan; Rany M Salem; Monkol Lek; Jason Flannick; Xueling Sim; Alisa Manning; Claes Ladenvall; Suzannah Bumpstead; Eija Hämäläinen; Kristiina Aalto; Mikael Maksimow; Marko Salmi; Stefan Blankenberg; Diego Ardissino; Svati Shah; Benjamin Horne; Ruth McPherson; Gerald K Hovingh; Muredach P Reilly; Hugh Watkins; Anuj Goel; Martin Farrall; Domenico Girelli; Alex P Reiner; Nathan O Stitziel; Sekar Kathiresan; Stacey Gabriel; Jeffrey C Barrett; Terho Lehtimäki; Markku Laakso; Leif Groop; Jaakko Kaprio; Markus Perola; Mark I McCarthy; Michael Boehnke; David M Altshuler; Cecilia M Lindgren; Joel N Hirschhorn; Andres Metspalu; Nelson B Freimer; Tanja Zeller; Sirpa Jalkanen; Seppo Koskinen; Olli Raitakari; Richard Durbin; Daniel G MacArthur; Veikko Salomaa; Samuli Ripatti; Mark J Daly; Aarno Palotie
Journal:  PLoS Genet       Date:  2014-07-31       Impact factor: 5.917

View more
  119 in total

Review 1.  Impact of Genes and Environment on Obesity and Cardiovascular Disease.

Authors:  Yoriko Heianza; Lu Qi
Journal:  Endocrinology       Date:  2019-01-01       Impact factor: 4.736

2.  The intrinsic instability of the hydrolase domain of lipoprotein lipase facilitates its inactivation by ANGPTL4-catalyzed unfolding.

Authors:  Katrine Z Leth-Espensen; Kristian K Kristensen; Anni Kumari; Anne-Marie L Winther; Stephen G Young; Thomas J D Jørgensen; Michael Ploug
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 11.205

3.  Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.

Authors:  Sergio Fazio; Jessica Minnier; Michael D Shapiro; Sotirios Tsimikas; Patrizia Tarugi; Maurizio R Averna; Marcello Arca; Hagai Tavori
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

4.  Adrenoceptor-related decrease in serum triglycerides is independent of PPARα activation.

Authors:  Maria Konstandi; Kyriakos E Kypreos; Tsutomu Matsubara; Eva Xepapadaki; Yatrik M Shah; Kristopher Krausz; Christina E Andriopoulou; Aristeidis Kofinas; Frank J Gonzalez
Journal:  FEBS J       Date:  2019-06-28       Impact factor: 5.542

5.  Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac Catheterization.

Authors:  Michael G Levin; Rachel L Kember; Renae Judy; David Birtwell; Heather Williams; Zolt Arany; Jay Giri; Marie Guerraty; Tom Cappola; Jinbo Chen; Daniel J Rader; Scott M Damrauer
Journal:  Circ Genom Precis Med       Date:  2018-11

Review 6.  Functional Assays to Screen and Dissect Genomic Hits: Doubling Down on the National Investment in Genomic Research.

Authors:  Kiran Musunuru; Daniel Bernstein; F Sessions Cole; Mustafa K Khokha; Frank S Lee; Shin Lin; Thomas V McDonald; Ivan P Moskowitz; Thomas Quertermous; Vijay G Sankaran; David A Schwartz; Edwin K Silverman; Xiaobo Zhou; Ahmed A K Hasan; Xiao-Zhong James Luo
Journal:  Circ Genom Precis Med       Date:  2018-04

7.  Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.

Authors:  Yu-Xin Xu; Valeska Redon; Haojie Yu; William Querbes; James Pirruccello; Abigail Liebow; Amy Deik; Kevin Trindade; Xiao Wang; Kiran Musunuru; Clary B Clish; Chad Cowan; Kevin Fizgerald; Daniel Rader; Sekar Kathiresan
Journal:  Atherosclerosis       Date:  2017-09-21       Impact factor: 5.162

8.  2018 Curt Stern Award Address.

Authors:  Sekar Kathiresan
Journal:  Am J Hum Genet       Date:  2019-03-07       Impact factor: 11.025

Review 9.  Genetics: ANGPTL3 deficiency protects from CAD.

Authors:  Irene Fernández-Ruiz
Journal:  Nat Rev Cardiol       Date:  2017-05-04       Impact factor: 32.419

Review 10.  ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.

Authors:  Ioannis Akoumianakis; Evangelia Zvintzou; Kyriakos Kypreos; Theodosios D Filippatos
Journal:  Curr Atheroscler Rep       Date:  2021-03-10       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.